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Abstract Dendritic cells (DC) are a heterogeneous population 
of specialized antigen presenting cells that exhibit complex 
trafficking properties. DC differentiated in vitro from both 
peripheral monocytes and CD34+ cells expressed mRNA for 
platelet activating factor (PAF) receptor. Expression of PAF 
receptor was increased by TNFa, a prototypic inflammatory 
cytokine that induces differentiation and in vivo mobilization of 
DC. PAF induced in vitro directional migration of DC obtained 
from both precursor cells through its specific receptor. Since DC 
are highly motile cells, protein chemoattractants as well as 
bioactive phospholipids are likely to contribute to tissue 
localization of DC, in vivo. 
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1. Introduction 
Dendritic cells (DC) are bone marrow-derived leukocytes 
specialized in antigen uptake, processing, and presentation 
to T lymphocytes. D C are believed to be indispensable for 
the initiation of a primary immune response [1,2]. Recently, 
techniques that allow the production of large quantities of 
D C , in vitro, were developed. D C cells can be derived from 
either CD34+ precursor cells (CD34-DC) or from circulating 
monocytes (mono-DC) by culturing them in the presence of a 
mixture of inflammatory cytokines and growth factors [3,4]. 
Although these cells share the key functions of specialized 
antigen presenting cells, an extensive comparison of D C de-
rived from different precursors has yet to be performed [4,5]. 
It has been known for a long time that D C are highly 
motile cells. D C progenitors enter the blood and seed non-
lymphoid tissues, where they develop into immature D C , with 
high ability in antigen uptake and processing, and yet low 
ability in T cell stimulation. Locally produced inflammatory 
cytokines (e.g. T N F and IL-1) and the encounter with an 
antigen promote the maturat ion and migration of D C to re-
gional lymph nodes via afferent lymphatics, where they 
present the antigens to unprimed T lymphocytes. Alterna-
tively, D C can migrate to the spleen through the blood 
[1,6]. A number of peptide chemotactic factors induce direc-
tional migration of D C , in vitro. These include 'classical' 
chemotactic factors, such as formylated peptides and C5a 
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and a selected pattern of C C (RANTES, MIP-loc, M I P - i p , 
MIP-3<x, MIP-5/HCC2, MCP-3 , and M D C ) and C X C 
(SDF-1) chemokines [7-11]. In a limited series of experiments, 
the chemotactic response of m o n o - D C and CD34-DC was 
comparable [8]. However, only CD34-DC, but not mono-
D C , expressed the chemokine receptor C C R 6 and migrated 
in response of MIP-3oc, its ligand [11,12]. 
In addition to proteins, some lipids/phospholipids are 
known to be potent chemotactic factors, in vitro and in 
vivo [13-16]. N o data are so far available on lipid chemotactic 
factors for DC. The goal of the present study was to inves-
tigate whether platelet activating factor (PAF), a bioactive 
phospholipid that plays a key role in leukocyte extravasation 
[14—16], could induce directional migration of mono-DC and 
CD34-DC, in vitro. 
2. Materials and methods 
2.1. Reagents 
Human recombinant RANTES was from PeproTech Inc. (Rocky 
Hill, NJ, USA). Human recombinant GM-CSF and TNFa were a 
generous gift from Sandoz (Basel, Switzerland), and BASF (Knoll, 
Germany), respectively. Cytokines were endotoxin free as assessed 
by the Limulus amebocyte assay. Platelet activating factor (1-O-al-
kyl-2-acetyl-OT-glycero-3-phosphochokine; cat. no. P9525) was from 
Sigma (St. Louis, MO, USA). WEB 2187 and l-O-octadecyl-2-ace-
tyl-(S)-glycero-3-phosphocholine (S-PAF) were from Boehringer In-
gelheim KG (Ingelheim am Rhein, Germany). 
2.2. DC culture 
Highly enriched blood monocytes ( > 9 5 % CD14+) were obtained 
and purified from buffy coats as previously described and cultured for 
7 days in RPMI (Biochrom, Berlin, Germany), 10% FCS (Hyclone, 
Logan, UT, USA) supplemented with 50 ng/ml GM-CSF and 10 ng/ 
ml IL-13. These cells (mono-DC) were > 80% CDla+, >90% MHC 
class 11+, < 10% CD14+, < 2 % CD3+ and < 4 % CD20+ [3,7-9]. CD-
34+ cells were purified from cord blood using Minimacs columns 
(Milteny Biotec, Germany). CD-341 cells were then cultured in 
RPMI 1640, 10% FCS in the presence of 50 ng/ml GM-CSF, 10 ng/ 
ml TNFa, and 50 ng/ml stem cell factor (Amgen Biological, Thou-
sand Oaks, CA, USA). After 14 days of culture, cells (CD34-DC) 
were 90% CDla 1 , 95% MHC class II 1 , 81% PAM-1 ' , and 85% 
CD80+ [4]. 
2.3. Northern blot analysis 
Total RNA was extracted by the guanidinium thiocyanate method, 
blotted and hybridized as described [8,9]. PAF receptor cDNA [17] 
was labeled with the Megaprime DNA labeling system (Amersham, 
Buckinghamshire, UK) with [a-32P]dCTP (3000 Ci/mmol, Amersham) 
as previously described [8,9]. 
2.4. Chemotaxis assay 
Cell migration was evaluated using a chemotaxis microchamber 
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technique as previously described [7-9]. Twenty-seven microliters of 
chemoattractant solution or control medium (RPMI 1640 with 1% 
FCS) were added to the lower wells of a chemotaxis chamber (Neu-
roprobe, Pleasanton, CA, USA). A polycarbonate filter (5 itm pore 
size; Neuroprobe) was layered onto the wells, covered with a silicon 
gasket and with the top plate. Fifty microliters of cell suspension (0.7-
1 X 106/ml) were seeded in the upper chamber. The chamber was in-
cubated at 37°C in humidified atmosphere in the presence of 5% CO2 
for 90 min. At the end of the incubation, filters were removed, stained 
with Diff-Quik (Baxter s.p.a., Rome, Italy) and five high power oil-
immersion fields (100 X) were counted. Results are expressed as the 
mean number of migrated cells in 10 high power fields. Each experi-
ment was performed in triplicate. 
3. Results and discussion 
PAF is a biologically active phospholipid that plays an 
important role in leukocyte recruitment [13-16]. To investi-
gate whether PAF could also activate DC, cells were gener-
ated from monocyte-enriched circulating mononuclear cells 
and from CD34+ cells. Fig. 1 shows that both mono-DC 
and CD34-DC express specific mRNA for PAF receptor of 
the expected size (~4.5 kbp), evaluated by Northern blot 
analysis. The level of expression was comparable to that ob-
served in human monocytes and polymorphonuclear cells, two 
leukocyte populations known to be activated by PAF [14,15]. 
It is interesting to note that 24 h stimulation with 20 ng/ml 
TNFoc increased the expression of PAF receptor in mono-DC. 
This is in agreement with previous results obtained with hu-
man monocytes [18]. 
Fig. 2 shows that DC express functional PAF receptors. 
PAF induced a concentration-dependent migration of mono-
DC, in vitro (Fig. 2A). The effect was statistically significant 
at 10 nM (P<0.01) and reached maximal levels at 100 nM 
PAF with a migration that was 73 ± 3% («= 3) of that ob-
served in response to an optimal concentration of RANTES 
(12 nM), a reference chemotactic factor [7,8,10]. PAF showed 
the bell-shaped dose-response curve typical for chemotactic 
agonists and was active in a concentration range similar to 
other phagocytic cells (not shown). The effect of PAF was 
completely inhibited by WEB 2187, a PAF receptor antago-
nist. Furthermore, the inactive PAF enantiomer, S-PAF 
[14,15], did not induce DC migration (Fig. 2B). These results 
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Fig. 1. Expression of PAF receptor in mono-DC and CD34-DC. 
Ten micrograms of total RNA was purified from DC obtained from 
blood circulating monocytes (mono-DC), from cord blood CD34+ 
cells (CD34+-DC) or from human monocytes (mono) and human 
granulocytes (PMN) and used in Northern blot analysis. Where in-
dicated, mono-DC were incubated with 20 ng/ml TNFa for 24 h. 
Results of two independent cultures of DC are shown. Ethidium 
bromide staining is reported below. 
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Fig. 2. Chemotactic activity of PAF for mono-DC and CD34-DC. 
A: DC ( lxl06 /ml) were tested for their ability to migrate across a 
polycarbonate filter in response to different concentrations of PAF. 
B: DC were tested for their migration to 100 nM PAF or 100 nM 
S-PAF. WEB 2187 (5 uM) was added directly to the cells and left 
for the entire duration of the assay. At the end of the incubation 
(90 min), the number of cells in 10 high power microscope immer-
sion fields was evaluated. Results of one experiment representative 
of three are shown. 
indicated that the effect of PAF on mono-DC was due to the 
activation of its specific receptor and not to a membrane 
effect. As expected on the basis of previous studies performed 
in other cell types, PAF also induced a rapid and transient 
increase in intracellular calcium concentration in fura-2-
loaded mono-DC (data not shown). To obtain indications 
as to the relative role of chemotaxis versus chemokinesis in 
induction of DC migration across filters, checkerboard anal-
ysis was performed. In these experiments, PAF was added 
only in the upper or in the lower compartment of the well, 
or at equal concentrations on both sides of the filter. As 
shown in Fig. 3A, significant cell migration was observed 
only in the presence of a positive concentration gradient 
(higher concentration in the lower well) of the chemoattrac-
tant, an observation consistent with a chemotactic effect. 
Fig. 2A shows that also CD34-DC migrated in response to 
PAF. The concentration curve and the magnitude of response 
of CD34-DC and mono-DC were comparable with respective 
chemotactic indices of 3.2±0.7 and 2.810.2 (« = 5). Similar 
results were obtained with CD34+ cells obtained from cord 
blood and bone marrow (data not shown). CD34+ progenitor 
cells can differentiate along multiple differentiation lineages 
[1,2,4]. To confirm that the cells migrating to PAF were in-
deed DC and not possibly contaminating leukocytes, the ex-
pression of CDla, a marker for immature DC [1], was used to 
obtain a purified DC population by fluorescent activated cell 
sorting. Fig. 3B shows that CD la+-sorted cells efficiently mi-
grated to PAF and to an optimal concentration of RANTES. 
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Fig. 3. Analysis of chemotactic response of mono-DC and CD34-
DC to PAF. A: For checkerboard analysis PAF (100 nM) was 
placed in the lower (positive gradient), in the upper (negative gra-
dient) or in both compartments (no gradient) of the chemotactic 
chamber. B: CDla+ CD34-DC were purified by FACS (CDla+-
sorted) and tested for their migration to PAF and to RANTES. In-
put cells (before purification) were tested in parallel. The average 
numbers ± S.D. of triplicate determinations of one experiment, rep-
resentative of three, are shown. 
Fig. 3B also shows that the level of response of C D la + -sor ted 
cells was comparable to that obtained with the starting input 
cell population. 
This study reports that mono-DC and CD34-DC express 
specific receptors and migrate to P A F . It is interesting to 
note that P A F receptor expression is upregulated by T N F . 
It was shown that T N F induces D C mobilization, in vivo 
[6], and that it has a profound effect on the stage of matura-
tion of D C [3]. P A F is known to be involved in proliferation 
and differentiation of various cells, including neurons and B 
lymphocytes [15,19]. The possible effect of P A F on D C cells 
differentiation has yet to be investigated. 
D C localize in peripheral tissues and subsequently migrate 
to lymphoid organs [1,6]. Rapid D C recruitment is a hallmark 
of inflammation caused by bacteria and their products at mu-
cosal surfaces [20]. Pro-inflammatory signals (e.g. LPS, IL-1 
and T N F ) induce a rapid mobilization of D C , in vivo [6]. The 
same inflammatory signals also induce the production of P A F 
and CC chemokines by different cell types [10,14,15]. D C 
produce chemokines [8-10,21] and in preliminary experiments 
we found that they also release P A F in response to a calcium 
ionophore (0.3 and 0.75 pmol/106 cells after 60 min incuba-
tion with medium or 1 u,M A23187, respectively). P A F and 
chemokines were shown to act in a synergistic manner in the 
induction of leukocyte migration [22,23]. It is likely that 
chemotactic signals of both protein and lipid nature con-
tribute to the rapid accumulation of these cells observed at 
sites of infection and tumor growth [1,2,6,20]. 
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